Sharp Therapeutics Corp.
SHRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 130.61% | -26.51% | 349.95% | 14.70% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 56.03% | 24.74% | 117.19% | 18.74% | |
| Operating Income | -56.03% | -24.74% | -117.19% | -18.74% | |
| Income Before Tax | -59.73% | 130.97% | -164.60% | 27.68% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -59.73% | 130.97% | -164.60% | 27.68% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -59.73% | 130.97% | -164.60% | 27.68% | |
| EBIT | -56.03% | -24.74% | -117.19% | -18.74% | |
| EBITDA | -56.45% | -25.49% | -132.39% | -21.27% | |
| EPS Basic | 99.72% | 100.15% | 98.69% | -11,694.36% | |
| Normalized Basic EPS | -- | 100.18% | 98.22% | -- | |
| EPS Diluted | 99.72% | 100.15% | 98.69% | -11,694.36% | |
| Normalized Diluted EPS | -- | 100.18% | 98.22% | -- | |
| Average Basic Shares Outstanding | -- | 21,196.20% | 20,159.01% | -- | |
| Average Diluted Shares Outstanding | 21,420.10% | 21,196.20% | 20,159.01% | -98.37% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |